0001209191-21-070986.txt : 20211222
0001209191-21-070986.hdr.sgml : 20211222
20211222184210
ACCESSION NUMBER: 0001209191-21-070986
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211220
FILED AS OF DATE: 20211222
DATE AS OF CHANGE: 20211222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Suria Hamza
CENTRAL INDEX KEY: 0001654495
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 211514373
MAIL ADDRESS:
STREET 1: C/O ANAPTYSBIO, INC.
STREET 2: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO, INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYSBIO INC
DATE OF NAME CHANGE: 20080828
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-12-20
0
0001370053
ANAPTYSBIO, INC
ANAB
0001654495
Suria Hamza
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO
CA
92121
1
1
0
0
President, CEO
Common Stock
2021-12-20
4
M
0
36645
1.12
A
105245
D
Common Stock
2021-12-20
4
S
0
11915
34.8935
D
93330
D
Common Stock
2021-12-20
4
S
0
19208
35.7547
D
74122
D
Common Stock
2021-12-20
4
S
0
5522
36.4046
D
68600
D
Employee Stock Option (Right to Buy)
1.12
2021-12-20
4
M
0
36645
0.00
D
2022-01-31
Common Stock
36645
0
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.26 to $36.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The stock option grant was issued on February 1, 2012, is fully vested and exercisable until its expiration date of January 31, 2022.
In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly.
/s/ Eric Loumeau, Attorney-in-Fact
2021-12-22